FUNDAMENTALS · Fundamentals · TW Healthcare

SCI Pharmtech (4119) Fundamentals 2026 — P/E 61.5x, Revenue Analysis | SniperIQ

SCI Pharmtech (4119) is a TW-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of NT$6.0B, trading at NT$49.80 on the TAI. This SniperIQ fundamentals page covers SCI Pharmtech's valuation (P/E 61.5x, P/B 1.1x), profitability (net margin 7.0%), revenue (NT

.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT$6.0B
P/E (TTM)61.5x
Net Margin7.0%
Revenue (FY25)NT
.3B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is SCI Pharmtech's market cap?

SCI Pharmtech (4119) has a market capitalization of approximately NT$6.0B, trading at NT$49.80 on the TAI. Market cap moves with the live share price.

What is SCI Pharmtech's P/E ratio?

SCI Pharmtech's trailing twelve-month P/E ratio is 61.5x, with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is SCI Pharmtech?

SCI Pharmtech runs a net profit margin of 7.0%, a gross margin of 24.9%, and an operating margin of 11.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does SCI Pharmtech generate?

SCI Pharmtech reported revenue of NT

.3B for fiscal year 2025, with net income of NT
07M and earnings per share (EPS) of 0.9. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does SCI Pharmtech pay a dividend?

SCI Pharmtech offers a trailing dividend yield of about 1.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is SCI Pharmtech financially healthy?

SCI Pharmtech carries a debt-to-equity ratio of 0.20x and a current ratio of 1.05x, with a market beta of 0.01. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is SCI Pharmtech a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For SCI Pharmtech (4119) the key facts are: market cap NT$6.0B, P/E 61.5x, revenue NT

.3B, 52-week range 39.6-63.2. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track SCI Pharmtech's full fundamentals live

Get SCI Pharmtech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.